We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-5.26%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$437M
AUM Growth
+$14M
Cap. Flow
+$60.4M
Cap. Flow %
13.81%
Top 10 Hldgs %
66.91%
Holding
28
New
6
Increased
6
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$34.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.1M
3
ONC
BeOne Medicines Ltd
ONC
+$17.4M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$11.5M
5
COGT icon
Cogent Biosciences
COGT
+$8.19M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$16.3M
2
INSM icon
Insmed
INSM
+$13M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$13M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.56M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$6.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$38.5M 8.81%
264,206
+24,892
+10% +$3.18M
AXSM icon
2
Axsome Therapeutics
AXSM
$11.8B
$36.1M 8.26%
942,571
– –
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.36B
$35.4M 8.1%
+3,343,107
New +$34.5M
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$30.5M 6.97%
953,396
-228,911
-19% -$6.7M
ARGX icon
5
argenx
ARGX
$53.8B
$27.9M 6.38%
73,526
-50,718
-41% -$16.3M
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.2B
$27.6M 6.31%
+283,000
New +$26.1M
INSM icon
7
Insmed
INSM
$23.5B
$26.2M 5.99%
1,326,368
-622,416
-32% -$13M
COGT icon
8
Cogent Biosciences
COGT
$6.68B
$24.9M 5.7%
2,758,975
+1,200,000
+77% +$8.19M
NUVL
9
DELISTED
Nuvalent
NUVL
$23.3M 5.32%
1,715,518
+377,125
+28% +$3.99M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$400M
$22.2M 5.08%
469,264
– –
ONC
11
BeOne Medicines Ltd
ONC
$32.4B
$18M 4.13%
+111,400
New +$17.4M
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$13.4M 3.07%
+2,245,891
New +$11.5M
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$12.5M 2.86%
1,833,950
-478,573
-21% -$3.66M
DBVT
14
DBV Technologies
DBVT
$870M
$12.3M 2.82%
+483,116
New +$8.08M
VRDN icon
15
Viridian Therapeutics
VRDN
$1.99B
$10.9M 2.5%
944,092
– –
ANNX icon
16
Annexon
ANNX
$950M
$10.9M 2.5%
2,892,600
+1,643,457
+132% +$5.02M
OLMA icon
17
Olema Pharmaceuticals
OLMA
$1B
$10.9M 2.49%
2,669,300
– –
ACAD icon
18
Acadia Pharmaceuticals
ACAD
$4.38B
$10.6M 2.42%
751,804
-405,013
-35% -$7.56M
TYRA icon
19
Tyra Biosciences
TYRA
$1.91B
$10.1M 2.32%
1,416,998
+132,008
+10% +$1.05M
AMRN
20
Amarin Corp
AMRN
$292M
$8.32M 1.9%
279,242
+72,580
+35% +$3.13M
KROS icon
21
Keros Therapeutics
KROS
$211M
$7.53M 1.72%
272,498
-124,413
-31% -$5.46M
TRVI icon
22
Trevi Therapeutics
TRVI
$2.71B
$4.57M 1.04%
+1,624,389
New +$3.99M
IOVA icon
23
Iovance Biotherapeutics
IOVA
$2.23B
$4.3M 0.98%
389,588
– –
VRNA
24
DELISTED
Verona Pharma
VRNA
$3.88M 0.89%
926,602
– –
TIL icon
25
Instil Bio
TIL
$50.3M
$3.11M 0.71%
33,695
– –
1
2

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q2 2022 Portfolio in Review

As of Q2 2022, Fairmount Funds Management held 28 positions worth $437M, up 3.3% from $423M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Fairmount Funds Management deployed $60.4M of net new capital in Q2 2022, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 3,343,107 shares worth $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $16.3M trimmed.

  • Fairmount Funds Management's largest Q2 2022 buy was BioCryst Pharmaceuticals: 3,343,107 shares worth $35.4M.
  • Fairmount Funds Management added most to Cogent Biosciences in Q2 2022, an estimated $8.19M increase.
  • Fairmount Funds Management's biggest Q2 2022 reduction was argenx, cutting an estimated $16.3M.
  • Fairmount Funds Management fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $13M.
  • Fairmount Funds Management's ten largest holdings make up 67% of its $437M portfolio in Q2 2022.
  • Fairmount Funds Management opened 6 new positions and closed 1 in Q2 2022.
  • Fairmount Funds Management's portfolio value rose 3.3% quarter-over-quarter to $437M.

Based on Fairmount Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.